Caisse DE Depot ET Placement DU Quebec Buys 242,560 Shares of Eli Lilly and Company $LLY

Key Points

• Caisse DE Depot ET Placement DU Quebec increased its stake in Eli Lilly by 46.4%, purchasing an additional 242,560 shares, bringing its total holdings to 765,030 shares valued at approximately $631.8 million.
• Analysts have issued mixed ratings for Eli Lilly, with a consensus rating of "Moderate Buy" and a target price averaging $950.17, reflecting varied confidence in the stock's future performance.
• Eli Lilly reported strong quarterly earnings, with $6.31 EPS exceeding expectations and a 37.6% year-over-year revenue increase, signaling robust company performance despite varying analyst opinions.

Caisse DE Depot ET Placement DU Quebec raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 46.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 765,030 shares of the company's stock after buying an additional 242,560 shares during the quarter. Eli Lilly and Company accounts for about 1.3% of Caisse DE Depot ET Placement DU Quebec's portfolio, making the stock its 14th largest position. Caisse DE Depot ET Placement DU Quebec owned approximately 0.08% of Eli Lilly and Company worth $631,846,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Corient IA LLC acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $570,000. LS Investment Advisors LLC boosted its position in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares in the last quarter. Prism Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $207,000. Hemington Wealth Management grew its holdings in shares of Eli Lilly and Company by 14.4% in the 1st quarter. Hemington Wealth Management now owns 985 shares of the company's stock valued at $813,000 after buying an additional 124 shares during the period. Finally, Bfsg LLC increased its position in shares of Eli Lilly and Company by 1.4% in the 1st quarter. Bfsg LLC now owns 2,959 shares of the company's stock valued at $2,444,000 after buying an additional 42 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Guggenheim reduced their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Cantor Fitzgerald cut their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Wall Street Zen upgraded Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Friday. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $710.7290 on Monday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market cap of $672.68 billion, a price-to-earnings ratio of 46.45, a price-to-earnings-growth ratio of 0.99 and a beta of 0.44. The stock's 50-day moving average is $754.70 and its 200-day moving average is $789.97. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the company earned $3.92 earnings per share. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.